Creation of a lysine-deficient LIGHT mutant with the capacity for site-specific PEGylation and low affinity for a decoy receptor

Biochemical and Biophysical Research Communications

Volumn 393, Issue 4, 2010, Pages 888-893

  Morishige, Tomohiro ^a   Yoshioka, Yasuo ^a   Inakura, Hiroshi ^a   Tanabe, Aya ^a   Yao, Xinglei ^a   Tsunoda, Shin ichi ^b   Tsutsumi, Yasuo ^a,b   Mukai, Yohei ^a   Okada, Naoki ^a   Nakagawa, Shinsaku ^a  

^a OSAKA UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

Author keywords

Bioconjugation; Cancer immunotherapy; Cytokine; Kinetic analysis; Protein engineering; Receptor selectivity

Indexed keywords

AMINO ACID; LYMPHOTOXIN; LYMPHOTOXIN BETA RECEPTOR; LYSINE; MACROGOL; MUTANT PROTEIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR 3; TUMOR NECROSIS FACTOR SUPERFAMILY MEMBER LIGHT; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; CONTROLLED STUDY; PRIORITY JOURNAL; PROTEIN STABILITY;

CELL LINE; HUMANS; LYSINE; PEPTIDE LIBRARY; POLYETHYLENE GLYCOLS; PROTEIN ENGINEERING; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 6B; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 14;

EID: 77949486399     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.02.119     Document Type: Article

References (26)

1. Harrop J.A., McDonnell P.C., Brigham-Burke M., et al. Herpesvirus entry mediator ligand (HVEM-L), a novel ligand for HVEM/TR2, stimulates proliferation of T cells and inhibits HT29 cell growth. J. Biol. Chem. 273 (1998) 27548-27556
2. Murphy M., Walter B.N., Pike-Nobile L., et al. Expression of the lymphotoxin beta receptor on follicular stromal cells in human lymphoid tissues. Cell Death Differ. 5 (1998) 497-505
3. Stopfer P., Mannel D.N., and Hehlgans T. Lymphotoxin-beta receptor activation by activated T cells induces cytokine release from mouse bone marrow-derived mast cells. J. Immunol. 172 (2004) 7459-7465
4. Yu P., Lee Y., Liu W., et al. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat. Immunol. 5 (2004) 141-149
5. Tamada K., Shimozaki K., Chapoval A.I., et al. LIGHT, a TNF-like molecule, costimulates T cell proliferation and is required for dendritic cell-mediated allogeneic T cell response. J. Immunol. 164 (2000) 4105-4110
6. Wu Y., Han B., Sheng H., et al. Clinical significance of detecting elevated serum DcR3/TR6/M68 in malignant tumor patients. Int. J. Cancer 105 (2003) 724-732
7. Pitti R.M., Marsters S.A., Lawrence D.A., et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396 (1998) 699-703
8. Bai C., Connolly B., Metzker M.L., et al. Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster. Proc. Natl. Acad. Sci. USA 97 (2000) 1230-1235
9. Macher-Goeppinger S., Aulmann S., Wagener N., et al. Decoy receptor 3 is a prognostic factor in renal cell cancer. Neoplasia 10 (2008) 1049-1056
10. Gill R.M., and Hunt J.S. Soluble receptor (DcR3) and cellular inhibitor of apoptosis-2 (cIAP-2) protect human cytotrophoblast cells against LIGHT-mediated apoptosis. Am. J. Pathol. 165 (2004) 309-317
11. Hayashi S., Miura Y., Nishiyama T., et al. Decoy receptor 3 expressed in rheumatoid synovial fibroblasts protects the cells against Fas-induced apoptosis. Arthritis Rheum. 56 (2007) 1067-1075
12. Morishige T., Yoshioka Y., Inakura H., et al. LIGHT protein suppresses tumor growth by augmentation of immune response. Immunol. Lett. 127 (2009) 33-38
13. Yoshioka Y., Tsutsumi Y., Nakagawa S., et al. Recent progress on tumor missile therapy and tumor vascular targeting therapy as a new approach. Curr. Vasc. Pharmacol. 2 (2004) 259-270
14. Mukai Y., Yoshioka Y., and Tsutsumi Y. Phage display and PEGylation of therapeutic proteins. Comb. Chem. High Throughput Screen. 8 (2005) 145-152
15. Yoshioka Y., Tsutsumi Y., Ikemizu S., et al. Optimal site-specific PEGylation of mutant TNF-alpha improves its antitumor potency. Biochem. Biophys. Res. Commun. 315 (2004) 808-814
16. Shibata H., Yoshioka Y., Ikemizu S., et al. Functionalization of tumor necrosis factor-alpha using phage display technique and PEGylation improves its antitumor therapeutic window. Clin. Cancer Res. 10 (2004) 8293-8300
17. Shibata H., Yoshioka Y., Ohkawa A., et al. Creation and X-ray structure analysis of the tumor necrosis factor receptor-1-selective mutant of a tumor necrosis factor-alpha antagonist. J. Biol. Chem. 283 (2008) 998-1007
18. Shibata H., Yoshioka Y., Abe Y., et al. The treatment of established murine collagen-induced arthritis with a TNFR1-selective antagonistic mutant TNF. Biomaterials 30 (2009) 6638-6647
19. Wang Y.S., Youngster S., Grace M., et al. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Adv. Drug Deliv. Rev. 54 (2002) 547-570
20. Yamamoto Y., Tsutsumi Y., Yoshioka Y., et al. Site-specific PEGylation of a lysine-deficient TNF-alpha with full bioactivity. Nat. Biotechnol. 21 (2003) 546-552
21. Rooney I.A., Butrovich K.D., Glass A.A., et al. The lymphotoxin-beta receptor is necessary and sufficient for LIGHT-mediated apoptosis of tumor cells. J. Biol. Chem. 275 (2000) 14307-14315
22. Morishige T., Yoshioka Y., Inakura H., et al. Creation of a LIGHT mutant with the capacity to evade the decoy receptor for cancer therapy. Biomaterials (2010) (Epub ahead of print)
23. Yoshioka Y., Watanabe H., Morishige T., et al. Creation of lysine-deficient mutant lymphotoxin-alpha with receptor selectivity by using a phage display system. Biomaterials 31 (2009) 1935-1943
24. Miller C.P., and Blau C.A. Using gene transfer to circumvent off-target effects. Gene Ther. 15 (2008) 759-764
25. Treetharnmathurot B., Ovartlarnporn C., Wungsintaweekul J., et al. Effect of PEG molecular weight and linking chemistry on the biological activity and thermal stability of PEGylated trypsin. Int. J. Pharm. 357 (2008) 252-259
26. Caliceti P., and Veronese F.M. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv. Drug Deliv. Rev. 55 (2003) 1261-1277